|
| Press Releases |
|
 |
|
| Tuesday, December 26, 2017 |
|
|
Nanobiotix: 2017 review and 2018 expected milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. more info >> |
|
|
FDA approves Nanobiotix's first Immuno-Oncology trial |
| A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) more info >> |
|
| Monday, November 13, 2017 |
|
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA. more info >> |
|
| Friday, November 10, 2017 |
|
|
Nanobiotix provides update on the global development of its lead product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3. more info >> |
|
| Monday, October 23, 2017 |
|
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. more info >> |
|
| Friday, September 29, 2017 |
|
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease. more info >> |
|
| Friday, September 1, 2017 |
|
|
Nanobiotix half year results for the six months ended 30 June 2017 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. more info >> |
|
| Friday, June 16, 2017 |
|
|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA. more info >> |
|
| Tuesday, June 6, 2017 |
|
|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
Dec 15, 2025 09:51 HKT/SGT
|
|
|
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 8:30 JST
|
|
|
韓国の主要人物・金載德氏がMOVA Chain支援を表明、エコシステム発展が新段階へ
Dec 13, 2025 13:00: JST
|
|
|
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
|
|
|
京東工業登陸港交所：業績與品牌雙賦能 長期成長潛力可期
Dec 12, 2025 17:05 HKT/SGT
|
|
|
京东工业登陆港交所：业绩与品牌双赋能 长期成长潜力可期
Dec 12, 2025 17:04 HKT/SGT
|
|
|
京東工業配售結果出爐：MRO龍頭實力領跑 全鏈條數智化解決方案釋放長期價值
Dec 12, 2025 17:00 HKT/SGT
|
|
|
京东工业配售结果出炉：MRO龙头实力领跑 全链条数智化解决方案释放长期价值
Dec 12, 2025 17:00 HKT/SGT
|
|
|
全鏈條服務+業績高增長彰顯實力 京東工業港交所上市釋放長期價值
Dec 12, 2025 15:54 HKT/SGT
|
|
|
全链条服务+业绩高增长彰显实力 京东工业港交所上市释放长期价值
Dec 12, 2025 15:54 HKT/SGT
|
|
|
首隻山水實景表演概念股 印象大紅袍啟動香港公開募股
Dec 12, 2025 15:01 HKT/SGT
|
|
|
首只山水实景表演概念股 印象大红袍启动香港公开募股
Dec 12, 2025 15:00 HKT/SGT
|
|
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT/SGT
|
|
|
雲頂新耀與海森生物簽署商業化服務協議及授權許可協議 推動商業化協同與多領域佈局
Dec 12, 2025 14:35 HKT/SGT
|
|
|
云顶新耀与海森生物签署商业化服务协议及授权许可协议 推动商业化协同与多领域布局
Dec 12, 2025 14:35 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
